Bio-Techne Corp Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.19 Intrinsic Value $52.20median of 6 methods · middle span $24-$73based on filings through 31 Mar 2026 Market Price $72.40Price as of 1 Oct 2026 OvervaluedIntrinsic value is 28% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $11.4B Enterprise Value $11.3B Shares Outstanding 157M diluted Moat Rating None Next Earnings Date9 Nov 2026 Last ex-dividend24 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Bio-Techne is principally a merger-arbitrage security following its agreement to be acquired by Merck KGaA for $73.00 per share in cash. The board-approved transaction offers a defined cash outcome but remains conditional on shareholder and regulatory approvals. Operating performance improved entering the transaction period, with fourth-quarter organic growth of 3%, including 8% organic growth in Diagnostics and Spatial Biology, although full-year organic revenue was flat and the annual filing identified unfavorable product mix and pricing pressure. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$50.00 Mean target$70.73 High · most bullish analyst$73.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $50.0015% A regulatory, shareholder, legal or financing-related obstacle delays or prevents completion. The shares then reprice toward standalone fundamentals, for which fiscal 2026 produced flat organic revenue and product-mix and pricing pressure. Base CaseCentral scenario $70.7360% Matches the consensus meanThe transaction receives shareholder and regulatory approvals and closes by late 2026 or early 2027 at $73.00 per share. Bull CaseUpside scenario $73.0025% Shareholders approve the transaction on September 23, required regulatory approvals arrive without burdensome remedies, and closing occurs toward the early end of the announced window. Investors receive the contracted $73.00 cash consideration with limited additional exposure to operating volatility. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |